Kezar Life Sciences is a biotechnology business based in the US. Kezar Life Sciences shares (KZR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.49 – a decrease of 0.4% over the previous week. Kezar Life Sciences employs 58 staff and has a trailing 12-month revenue of around $7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.49 |
|---|---|
| 52-week range | $5.20 - $11.35 |
| 50-day moving average | $7.13 |
| 200-day moving average | $7.48 |
| Wall St. target price | $19.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-13.50 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.38 from 2024-11-19
| 1 week (2024-11-14) | -1.86% |
|---|---|
| 1 month (2024-10-21) | 831.47% |
| 3 months (2024-08-21) | 1,068.83% |
| 6 months (2024-05-21) | 851.15% |
| 1 year (2023-11-21) | 738.64% |
|---|---|
| 2 years (2022-11-21) | -90.15% |
| 3 years (2021-11-19) | 139.7 |
| 5 years (2019-11-21) | 26 |
| Revenue TTM | $7 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -28.07% |
| Return on equity TTM | -51.48% |
| Profit margin | 0% |
| Book value | $25.77 |
| Market Capitalization | $54.9 million |
TTM: trailing 12 months
We're not expecting Kezar Life Sciences to pay a dividend over the next 12 months.
Kezar Life Sciences's shares were split on a 1:10 basis on 29 October 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kezar Life Sciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kezar Life Sciences shares which in turn could have impacted Kezar Life Sciences's share price.
Over the last 12 months, Kezar Life Sciences's shares have ranged in value from as little as $5.202 up to $11.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kezar Life Sciences's is 0.217. This would suggest that Kezar Life Sciences's shares are less volatile than average (for this exchange).
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.